Executives are discussing the financial results of the Company for the marketing plan.

Midatech Pharma Ads (NASDAQ:MTP) down -4.4% to close at the price of $0.44. The stock has a market capitalization of $26.57 Million however its outstanding shares are 61.08 Million. The company’s beta value stood at 0.

Midatech Pharma Ads (NASDAQ:MTP) as of current trade, has shown weekly performance of -22.04% which was maintained at 295.1% in one month period. Year to date performance remained at 180.65%. During the past three months the stock gain 109.24%, however six months performance of the stock remained at -35.07%. Midatech Pharma Ads (NASDAQ:MTP)’s price sits 91.8% above from its SMA 50 of $0.2594 and -8.42% far from the SMA 200 which is at $0.3818.

Currently Midatech Pharma Ads (NASDAQ:MTP)’s shares owned by insiders are 32.1%, whereas shares owned by institutional owners are 0%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0%.

The stock is trading -75.83% away from its 52 week high of $1.80 and 321.92% far from the stock’s low point over the past 52 weeks, which was $0.10.

The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. Midatech Pharma Ads (NASDAQ:MTP)’s price to earnings ratio stood at 0. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. A low P/E can indicate either that a company may currently be undervalued or that the company is doing exceptionally well relative to its past trends.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E. Midatech Pharma Ads (NASDAQ:MTP) has a current PEG of 0. Midatech Pharma Ads (NASDAQ:MTP)’s price to sales ratio for trailing twelve month stands at 0, whereas its price to book ratio for the most recent quarters is at 0.43. However the company’s price to cash per share for most recent quarter stands at 0. Its price to free cash flow for trailing twelve months is 0.